MARKET

NKTR

NKTR

Nektar Therapeutics
NASDAQ
0.6364
+0.0296
+4.88%
After Hours: 0.6500 +0.0136 +2.14% 19:58 04/17 EDT
OPEN
0.6000
PREV CLOSE
0.6068
HIGH
0.6569
LOW
0.6000
VOLUME
2.00M
TURNOVER
--
52 WEEK HIGH
1.928
52 WEEK LOW
0.4320
MARKET CAP
118.44M
P/E (TTM)
-1.1003
1D
5D
1M
3M
1Y
5Y
1D
Nektar management to meet virtually with B. Riley
TipRanks · 3d ago
Weekly Report: what happened at NKTR last week (0407-0411)?
Weekly Report · 5d ago
Nektar management to meet virtually with B. Riley
TipRanks · 04/11 15:30
Why Is Nektar (NKTR) Down 38.8% Since Last Earnings Report?
NASDAQ · 04/11 15:30
Nektar upgraded at Jefferies ahead of mid-stage readout for eczema drug
Seeking Alpha · 04/11 15:23
Assessing Nektar Therapeutics: Insights From 5 Financial Analysts
Benzinga · 04/11 14:00
Nektar Therapeutics Raised to Buy From Hold by Jefferies
Dow Jones · 04/11 12:44
Nektar Therapeutics Price Target Raised to $2.00/Share From $1.00 by Jefferies
Dow Jones · 04/11 12:44
More
About NKTR
More
Nektar Therapeutics is a clinical-stage biotechnology company. It is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase IIb clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. It is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.
Recently
Symbol
Price
%Change

Webull offers Nektar Therapeutics stock information, including NASDAQ: NKTR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NKTR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NKTR stock methods without spending real money on the virtual paper trading platform.